Featured Content

Is Real-World Evidence a Complement to Randomized Clinical Trials?

Use of real-world data has the potential to accelerate drug and device approvals in rare diseases and advance precision medicine initiatives.

Gene-Delivery Method Generates Immune Checkpoint Antibodies In Vivo

In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody CTLA-4; DMabs may one day rival traditional mAbs.

Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.

Cancer Recurrence: Tackling a Valid Survivor Fear

Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with ...

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.

More Features>>>

Prostate Cancer Resources

Special Edition Issue

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs